SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Ades who wrote (567)3/31/1997 1:58:00 PM
From: John Metcalf   of 6136
 
Good question, Michael. Perhaps one of the more knowledgable readers can give a definitive answer.

Combining two approved PI's could be done now, but would be an off-label usage. Doing so would not be illegal, as I understand it. More prudent patients and doctors would wait until there is FDA guidance or clinical trial results to guide double PI therapy.

Because PI users are concerned about resistance developing eventually, my guess is that most would wait before using, and possibly exhausting, recourse to a protease inhibitor.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News